Jupiter Asset Management Ltd. Acquires 221,158 Shares of Adaptive Biotechnologies Corporation $ADPT

Jupiter Asset Management Ltd. boosted its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 442.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 271,128 shares of the company’s stock after acquiring an additional 221,158 shares during the period. Jupiter Asset Management Ltd.’s holdings in Adaptive Biotechnologies were worth $4,056,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in ADPT. Brighton Jones LLC grew its stake in shares of Adaptive Biotechnologies by 3.1% in the third quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock worth $349,000 after acquiring an additional 700 shares during the period. Bouvel Investment Partners LLC boosted its holdings in Adaptive Biotechnologies by 2.2% in the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock worth $641,000 after purchasing an additional 904 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Adaptive Biotechnologies by 3.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock worth $355,000 after purchasing an additional 910 shares during the last quarter. California State Teachers Retirement System grew its position in Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after purchasing an additional 933 shares during the period. Finally, Captrust Financial Advisors raised its stake in Adaptive Biotechnologies by 7.6% during the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Trading Down 5.3%

NASDAQ ADPT opened at $15.20 on Friday. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -38.00 and a beta of 2.18. The company’s 50 day moving average is $16.91 and its two-hundred day moving average is $15.59.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.23) earnings per share. Sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other news, insider Francis Lo sold 79,590 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $17.73, for a total value of $1,411,130.70. Following the completion of the transaction, the insider owned 315,978 shares of the company’s stock, valued at $5,602,289.94. This represents a 20.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kyle Piskel sold 2,145 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total value of $39,596.70. Following the sale, the chief financial officer directly owned 216,637 shares in the company, valued at $3,999,119.02. This trade represents a 0.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 906,556 shares of company stock worth $16,143,664. 6.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ADPT. Morgan Stanley began coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target on the stock. Guggenheim boosted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Wall Street Zen raised shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. JPMorgan Chase & Co. raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Finally, BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.